Company Overview of Hellman & Friedman LLC
Hellman & Friedman LLC is a private equity firm specializing in leveraged recapitalizations, acquisitions, buys and builds, traditional buyouts, financial restructurings, growth investments, and numerous types of minority investments. It invests in public and private companies. The firm makes investments in marketing and professional services, asset management and other business and financial services, insurance, media, energy, healthcare, companies running clinical trials for pharmaceutical companies, industrials, vertical software and information services industries, data services, Internet and digital media, and media. It targets investments in companies based in North America with a focu...
One Maritime Plaza
San Francisco, CA 94111
Founded in 1984
Key Executives for Hellman & Friedman LLC
Chief Executive Officer, Managing Director, Chairman of Investment Committee, and Chairman of Compensation Committee
Managing Director and Chief Financial Officer
Managing Director and Chief Legal Officer
Managing Director, Deputy Chief Executive Officer, Member of Compensation Committee, and Member of Investment Committee
Managing Director and Member of Investment Committee
Compensation as of Fiscal Year 2016.
Hellman & Friedman LLC Key Developments
Private Equity Fund Reportedly Seeks Acquisition Of Zabka Polska From Mid Europa Partners
Dec 21 16
Private equity fund reportedly are seeking acquisition of Zabka Polska sp. z o.o. from Mid Europa Partners LLP. Puls Biznesu daily reported that the private equity funds want to buy Zabka Polska from Mid Europa Partners. The first bids were filed on December 19, 2016. Among the funds interested in the issue are TPG Capital, L.P., BC Partners, Hellman & Friedman LLC and CVC Capital Partners Limited. Apart from them, CP ALL Public Company Limited (SET:CPALL) is mentioned among the prospective buyers A source of Puls Biznesu claims that PLN 5 billion is regarded as a starting point in negotiations with the prospective investor.
Pharmaceutical Product Development Reportedly Exploring Sale
Dec 9 16
Pharmaceutical Product Development, LLC is reportedly exploring sale. Pharmaceutical Product Development LLC is exploring a sale that could value the drug-research company at about $5 billion. Pharmaceutical Product Development hired The Goldman Sachs Group, Inc. (NYSE:GS), J.P. Morgan Chase & Co. and Centerview Partners LLC to help it find a buyer, people familiar with the matter said. The banks plan to start sounding out suitors in December. A deal could be reached in the first quarter, assuming there is one, the people said. Pharmaceutical Product Development’s owners, The Carlyle Group LP (NasdaqGS:CG) and Hellman & Friedman LLC, may opt to take it public instead, but they aren’t actively preparing for an IPO, the people said. A $5 billion deal would deliver a return of more than three times the firms’ investment, when accounting for four dividends PPD has paid them.
Hellman & Friedman LLC Presents at PEI Operating Partners Forum: New York, Oct-19-2016 01:45 PM
Oct 17 16
Hellman & Friedman LLC Presents at PEI Operating Partners Forum: New York, Oct-19-2016 01:45 PM. Venue: Convene Conference Center, 730 Third Avenue, The TIAA-CREF building, New York, NY 10017, United States. Speakers: Ricardo Gonzalez, Principal.
Similar Private Companies By Industry
Recent Private Companies Transactions